Back

The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors: from cells to patients Lipid-Lowering Agents ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Osnat Itzhaki Ben Zadok

Rabin Medical Centre, Petah Tikva (Israel)

4 More presentations in this session

Presentation thumbnail
State of the Art - PCSK9 in inhibitors therapy in clinical therapy
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia.
Mrs A. Tsouka (Ioannina, GR)
Abstract Slides Video
Presentation thumbnail
Treatment of Hypercholesterolaemia with PCSK9 Inhibitors in Denmark. Assessment of real-life data; Extent and Efficacy after the first years of clinical use
Doctor S. Mulverstedt (Copenhagen, DK)
Abstract
Presentation thumbnail
Positioning PCSK9 inhibitors therapy in clinical practice.
Professor K. Ray (London, GB)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibitors: from cells to patients

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
What’s new in LDL lowering?
thumbnail
Congress Presentation
Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources